Emergence of bullous pemphigoid under treatment of mycosis fungoides with mogamulizumab
Abstract Mycosis fungoides (MF) is the most common cutaneous T cell lymphoma. Since 2018, mogamulizumab, an antibody directed to to the chemokine receptor CCR4, is licensed for the treatment of MF. Treatment with mogamulizumab is associated with the precipiation of different types of skin rashes sum...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | JEADV Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jvc2.570 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!